XXXX prevalence following recovery from @entity2106 and aHUS.

@entity9818 @entity32 @entity1 @entity308 @entity882 @entity16 @entity2105 @entity5714 @entity19355 @entity1381 @entity10 @entity2106
UNASSIGNED: @entity2106 ( @entity2106 ) and atypical @entity1381 (aHUS) are distinct clinical disorders characterized by @entity5714 , @entity882 , microthrombi, and @entity16 . @entity2106 is characterized by a low @entity2105 activity level at diagnosis of <10  % @entity2105 activity, while aHUS is characterized as having >10  % @entity2105 activity. Despite clinical remission, survivors of @entity9818 suffer significant comorbidity and decreased quality of life (QOL) than their healthy counterparts. The reason for this is unclear. Is it a lingering effect from their initial acute episode or ongoing subclinical @entity32 despite clinical remission? Common clinical complaints validated in practice include @entity308 , deficits in memory, concentration, mood, and mental endurance. We suspect @entity10 may be an important clinical tool toward understanding @entity1 morbidity and decreased QOL. To date, no studies report @entity10 frequency or severity in this population. To answer this question, adult @entity1 >3  months since their last acute episode of @entity2106 or aHUS were approached to take a @entity10 Impact Test (HIT-6) survey. Between June 1, 2013 and May 30, 2014, 31 @entity1 in remission (21 @entity1 with prior @entity2106 and 10 @entity1 with prior aHUS) completed the HIT-6 survey. The survey scores were then compared to the HIT-6 normative population data established by Qualitymetric incorporated. Overall, @entity2106 @entity1 had a significantly higher average HIT-6 score of 59.9 compared to an average HIT-6 score of 51 seen in sex-matched controls (SD 9.6, p value 0.002). No significant difference was seen in the HIT-6 scores of aHUS @entity1 . Of @entity2106 @entity1 studied, approximately 57  % (12/21) had three or more episodes and were >24  months since the last episode. The average time since last acute episode in @entity2106 @entity1 was 37.5  months. There was no significant correlation between @entity2106 survivor @entity19355 of prior episodes (1, 2, or >3) or timing from the last episode (3-6, 7-12, 13-24, or >24  months). About 19/21 (90  %) @entity1 , who are @entity2106 survivors, also had a normal @entity2105 activity level (>10  %) on the day of the survey. Our study suggests that @entity10 have significant impact on @entity2106 survivors and should be followed in the clinical setting to prevent undue @entity1 morbidity. Larger studies are needed to understand how @entity10 impact long-term survival and risk of relapse.
